TrialJournal of hematology & oncology2017

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.

Jian Hou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.